CD19 and B-cell chronic lymphocytic leukemia: Analyses of peripheral blood samples from cases of CLL confirmed that CD19+ B cells with the malignant CD5+ phenotype, which predominate in patients’ PBMC, had low levels of CD22, and their expression of Siglec‐10 was also found to be somewhat reduced (Figure S4b).